Literature DB >> 32102022

Distribution of functional opioid receptors in human dorsal root ganglion neurons.

Jamie K Moy1, Jane E Hartung1, Melissa G Duque1, Rob Friedman1, Vidhya Nagarajan1, Emanuel Loeza-Alcocer1, H Richard Koerber1, Thomas Christoph2, Wolfgang Schröder2, Michael S Gold1.   

Abstract

Preclinical evidence has highlighted the importance of the μ-opioid peptide (MOP) receptor on primary afferents for both the analgesic actions of MOP receptor agonists, as well as the development of tolerance, if not opioid-induced hyperalgesia. There is also growing interest in targeting other opioid peptide receptor subtypes (δ-opioid peptide [DOP], κ-opioid peptide [KOP], and nociceptin/orphanin-FQ opioid peptide [NOP]) on primary afferents, as alternatives to MOP receptors, which may not be associated with as many deleterious side effects. Nevertheless, results from several recent studies of human sensory neurons indicate that although there are many similarities between rodent and human sensory neurons, there may also be important differences. Thus, the purpose of this study was to assess the distribution of opioid receptor subtypes among human sensory neurons. A combination of pharmacology, patch-clamp electrophysiology, Ca imaging, and single-cell semiquantitative polymerase chain reaction was used. Our results suggest that functional MOP-like receptors are present in approximately 50% of human dorsal root ganglion neurons. δ-opioid peptide-like receptors were detected in a subpopulation largely overlapping that with MOP-like receptors. Furthermore, KOP-like and NOP-like receptors are detected in a large proportion (44% and 40%, respectively) of human dorsal root ganglion neurons with KOP receptors also overlapping with MOP receptors at a high rate (83%). Our data confirm that all 4 opioid receptor subtypes are present and functional in human sensory neurons, where the overlap of DOP, KOP, and NOP receptors with MOP receptors suggests that activation of these other opioid receptor subtypes may also have analgesic efficacy.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32102022      PMCID: PMC7305987          DOI: 10.1097/j.pain.0000000000001846

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   7.926


  74 in total

1.  Agonist-directed interactions with specific beta-arrestins determine mu-opioid receptor trafficking, ubiquitination, and dephosphorylation.

Authors:  Chad E Groer; Cullen L Schmid; Alex M Jaeger; Laura M Bohn
Journal:  J Biol Chem       Date:  2011-07-14       Impact factor: 5.157

2.  Selective blockage of delta opioid receptors prevents the development of morphine tolerance and dependence in mice.

Authors:  E E Abdelhamid; M Sultana; P S Portoghese; A E Takemori
Journal:  J Pharmacol Exp Ther       Date:  1991-07-01       Impact factor: 4.030

3.  Differential in vivo potencies of naltrexone and 6beta-naltrexol in the monkey.

Authors:  M C Holden Ko; Mary F Divin; Heeseung Lee; James H Woods; John R Traynor
Journal:  J Pharmacol Exp Ther       Date:  2005-10-28       Impact factor: 4.030

Review 4.  Delta and kappa opioid receptors as suitable drug targets for pain.

Authors:  Todd W Vanderah
Journal:  Clin J Pain       Date:  2010-01       Impact factor: 3.442

5.  The Cancer Chemotherapeutic Paclitaxel Increases Human and Rodent Sensory Neuron Responses to TRPV1 by Activation of TLR4.

Authors:  Yan Li; Pavel Adamek; Haijun Zhang; Claudio Esteves Tatsui; Laurence D Rhines; Petra Mrozkova; Qin Li; Alyssa K Kosturakis; Ryan M Cassidy; Daniel S Harrison; Juan P Cata; Kenneth Sapire; Hongmei Zhang; Ross M Kennamer-Chapman; Abdul Basit Jawad; Andre Ghetti; Jiusheng Yan; Jiri Palecek; Patrick M Dougherty
Journal:  J Neurosci       Date:  2015-09-30       Impact factor: 6.167

6.  Kappa- and delta-opioids block sympathetically dependent hyperalgesia.

Authors:  Y O Taiwo; J D Levine
Journal:  J Neurosci       Date:  1991-04       Impact factor: 6.167

7.  Human sensory neurons: Membrane properties and sensitization by inflammatory mediators.

Authors:  Steve Davidson; Bryan A Copits; Jingming Zhang; Guy Page; Andrea Ghetti; Robert W Gereau
Journal:  Pain       Date:  2014-06-25       Impact factor: 6.961

8.  Ligand directed signaling differences between rodent and human κ-opioid receptors.

Authors:  Selena S Schattauer; Mayumi Miyatake; Haripriya Shankar; Chad Zietz; Jamie R Levin; Lee-Yuan Liu-Chen; Vsevolod V Gurevich; Mark J Rieder; Charles Chavkin
Journal:  J Biol Chem       Date:  2012-10-19       Impact factor: 5.157

9.  Src phosphorylation of micro-receptor is responsible for the receptor switching from an inhibitory to a stimulatory signal.

Authors:  Lei Zhang; Hui Zhao; Yu Qiu; Horace H Loh; Ping-Yee Law
Journal:  J Biol Chem       Date:  2008-11-24       Impact factor: 5.157

10.  Comparative transcriptome profiling of the human and mouse dorsal root ganglia: an RNA-seq-based resource for pain and sensory neuroscience research.

Authors:  Pradipta Ray; Andrew Torck; Lilyana Quigley; Andi Wangzhou; Matthew Neiman; Chandranshu Rao; Tiffany Lam; Ji-Young Kim; Tae Hoon Kim; Michael Q Zhang; Gregory Dussor; Theodore J Price
Journal:  Pain       Date:  2018-07       Impact factor: 7.926

View more
  14 in total

1.  GCaMP as an indirect measure of electrical activity in rat trigeminal ganglion neurons.

Authors:  Jane E Hartung; Michael S Gold
Journal:  Cell Calcium       Date:  2020-05-30       Impact factor: 6.817

2.  Pleiotropic Effects of Kappa Opioid Receptor-Related Ligands in Non-human Primates.

Authors:  Mei-Chuan Ko; Stephen M Husbands
Journal:  Handb Exp Pharmacol       Date:  2020-12-04

3.  Voltage-gated calcium currents in human dorsal root ganglion neurons.

Authors:  Jane E Hartung; Jamie K Moy; Emanuel Loeza-Alcocer; Vidhya Nagarajan; Ruth Jostock; Thomas Christoph; Wolfgang Schroeder; Michael S Gold
Journal:  Pain       Date:  2021-08-27       Impact factor: 7.926

4.  Sympathetic modulation of tumor necrosis factor alpha-induced nociception in the presence of oral squamous cell carcinoma.

Authors:  Megan Atherton; Stella Park; Nicole L Horan; Samuel Nicholson; John C Dolan; Brian L Schmidt; Nicole N Scheff
Journal:  Pain       Date:  2022-04-20       Impact factor: 7.926

5.  Spatial transcriptomics of dorsal root ganglia identifies molecular signatures of human nociceptors.

Authors:  Diana Tavares-Ferreira; Stephanie Shiers; Pradipta R Ray; Andi Wangzhou; Vivekanand Jeevakumar; Ishwarya Sankaranarayanan; Anna M Cervantes; Jeffrey C Reese; Alexander Chamessian; Bryan A Copits; Patrick M Dougherty; Robert W Gereau; Michael D Burton; Gregory Dussor; Theodore J Price
Journal:  Sci Transl Med       Date:  2022-02-16       Impact factor: 19.319

Review 6.  Skin-Nerve Co-Culture Systems for Disease Modeling and Drug Discovery.

Authors:  Stacey C Schutte; Feni Kadakia; Steve Davidson
Journal:  Tissue Eng Part C Methods       Date:  2021-02-02       Impact factor: 3.056

7.  Exploiting Injury-Induced Peripheral Opioid Receptor Changes in Novel Analgesic Development for Chronic Pain.

Authors:  Craig T Hartrick
Journal:  Front Pain Res (Lausanne)       Date:  2022-04-26

8.  Agonists Specific for κ-Opioid Receptor Induces Apoptosis of HCC Cells Through Enhanced Endoplasmic Reticulum Stress.

Authors:  Mengyuan Tan; Hanyu Wang; Cheng Gao; Zhen Jiang; Ying Yin; Ruyi Xing; Ling Hu; Jiegou Xu; Min Zhang; Yanhu Xie
Journal:  Front Oncol       Date:  2022-03-31       Impact factor: 6.244

9.  A ligand-receptor interactome platform for discovery of pain mechanisms and therapeutic targets.

Authors:  Andi Wangzhou; Candler Paige; Sanjay V Neerukonda; Dhananjay K Naik; Moeno Kume; Eric T David; Gregory Dussor; Pradipta R Ray; Theodore J Price
Journal:  Sci Signal       Date:  2021-03-16       Impact factor: 8.192

Review 10.  Studying human nociceptors: from fundamentals to clinic.

Authors:  Steven J Middleton; Allison M Barry; Maddalena Comini; Yan Li; Pradipta R Ray; Stephanie Shiers; Andreas C Themistocleous; Megan L Uhelski; Xun Yang; Patrick M Dougherty; Theodore J Price; David L Bennett
Journal:  Brain       Date:  2021-06-22       Impact factor: 15.255

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.